Deadline Approaching: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. SmithBusiness Wire • Wednesday
Levi & Korsinsky Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNCAccesswire • Wednesday
The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Case Against Revance Therapeutics, Inc.Accesswire • Wednesday
RVNC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • Wednesday
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & KorsinskyAccesswire • Wednesday
REVANCE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. and Encourages Investors to Contact the FirmGlobeNewsWire • Wednesday
Stockholder Notice: Robbins LLP Informs Stockholders of the Revance Therapeutics, Inc. Class Action LawsuitPRNewsWire • Tuesday
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNCAccesswire • Tuesday
Law Offices of Frank R. Cruz Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class ActionBusiness Wire • Tuesday
March 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against - RVNCAccesswire • Tuesday
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Revance Therapeutics, Inc. (RVNC)GlobeNewsWire • Tuesday
Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNCAccesswire • Tuesday
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • Tuesday
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class ActionBusiness Wire • Monday
Law Offices of Howard G. Smith Encourages Revance Therapeutics, Inc. (RVNC) Investors To Inquire About Securities Fraud Class ActionBusiness Wire • Monday
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNCAccesswire • Monday
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Revance Therapeutics, Inc. (RVNC) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmGlobeNewsWire • Monday
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • Monday
Teoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in CashPRNewsWire • Monday
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Revance Therapeutics, Inc. and Certain Officers -RVNCAccesswire • 01/03/25
REVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNCBusiness Wire • 12/17/24
Shareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public ShareholdersBusiness Wire • 12/12/24
Crown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per sharePRNewsWire • 12/12/24
Crown Laboratories and Revance Enter into Amended and Restated Merger AgreementBusiness Wire • 12/09/24
